Variability of arterial hypertension as an additional factor to cardiovascular risk in atrial fibrillation

  • N. Ya. Dotsenko State institution "Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine"
  • L. V. Herasymenko State institution "Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine"
  • I. A. Shekhunova State institution "Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine"
  • S. S. Boev State institution "Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine"
  • А. V. Molodan State institution "Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine"
  • A. Ya. Malinovskaya State institution "Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine"
  • O. V. Yatsenko State institution "Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine"
Keywords: blood pressure variability, аrterial hypertension, atrial fibrillation

Abstract

The article presents a review of the literature on the role of hypertension in the mechanisms of atrial fibrillation, therelationshipbetweenwhichincreases the risk of cardiovascular disease and mortality. The importance of taking into account the increased variability of BP in the development of target organ damage and adverse cardiovascular events is shown. Approaches to the choice of antihypertensive therapy in patients with hypertension and atrial fibrillation have been identified. It has been found that reducing BP variability can be added as one of the most important strategies in the treatment of hypertension and atrial fibrillation.

References

Höcht C. Blood Pressure Variability: Prognostic Value and Therapeutic Implications. ISRN Hypertension 2013; vol. 2013: article ID 398485.

McMullan CJ, Bakris GL, Phillips RA et al. Association of BP variability with mortality among African Americans with CKD. Clinical Journal of the American Society 7. of Nephrology 2013; 8 (5): 731–738.

Kawai T, Ohishi M, Kamide K. Differences between daytime and nighttime blood pressure variability regarding systemic atherosclerotic change and renal function. Hypertension Research 2013; 36: 232–239.

Cipollini F, Arcangeli E, Seghieri G. Left atrial dimension is related to blood pressure variability in newly diagnosed untreated hypertensive patients. Hypertens Res. 2016; 39 (8): 583–587.

Dedov DV, Ivanov AP, Elgardt IA Predictors of atrial fibrillation recurrence in patients with arterial hypertension. Doctor. 2011. 5: 83–85.

Buchbinder W, Sugarman H. Arterial blood pressure in cases of auricular fibrillation, measured directly. Arch. Intern. Med. 1940; 66: 625–642.

Olbers J, Gille A, Ljungman P et al. High beat-to-beat blood pressure variability in atrial fibrillation compared to sinus rhythm. Blood Pressure.2018; 27 (5): 249–255. https://doi.org/ 10.1080/08037051.2018.1436400.

Aletti F, Hammond RL, Sala-Mercado JA et al. Cardiac output is not a significant source of low frequency mean arterial pressure variability. Physiol. Meas. 2013; 34: 1207–1216. doi: 10.1088/0967-3334/34/9/1207.

Bruno RM, Ghiadoni L, Seravalle G et al. Sympathetic regulation of vascular function in health and disease. Front Physio.2012; 3: 284. https://doi.org/10.3389/fphys.2012.00284.

Wasmund SL, Li JM, Page RL et al. Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects. Circulation.2003; 107: 2011–2015. doi: 10.1161/01.CIR.0000064900.76674.CC.

Segerson NM, Sharma N, Smith ML et al. The effects of rate and irregularity on sympathetic nerve activity in human subjects. Heart Rhythm. 2007;4:20–26. doi: 10.1016/j.hrthm.2006.09.017.

Lieder H, Breithardt G, Heusch G. Fatal attraction: A brief pathophysiology of the interaction between atrial fibrillation and myocardial ischemia. Int. J. Cardiol. 2018; 254: 132–135.

Clark DM, Plumb VJ, Epstein AE et al. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J. Am. Coll. Cardiol.1997; 30: 1039–1045. doi: 10.1016/s0735-1097(97)00254-4.

Yusuf S, Hawken S, Ounpuu S et al. INTERHEARTStudyInvestigatorsEffectofpotentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937–952. doi: 10.1016/S0140-6736 (04) 17018-9.

Li ZY, Taviani V, Tang T et al. The mechanical triggers of plaque rupture: shear stress vs pressure gradient. BJR. 2009; 82: 39–45. doi: org/10.1259/bjr/15036781.

Xiong H, Liu X, Tian X et al. A numerical study of the effect of varied blood pressure on the stability of carotid atherosclerotic plaque. Biomed. Eng. Online.2014; 13: 152. doi: 10.1186/1475-925X-13-152.

Lee S, Choi Y-J, Choi E-K et al. Blood pressure variability and incidence of new-onset atrial fibrillation. A nationwide population-based study. Hypertension. 2019; 75: 309–315. https://doi. org/10.1161/HYPERTENSIONAHA.119.13708.

Nimtsovych TI, Mikhaliev КО, Kravchenko AM et al. Visit-to-visit blood pressure variability in rural males with arterial hypertension: the possibilities of modifying in real clinical settings. Clinical and preventive medicine. 2020; 2 (12): 90–109. https://doi.org/10.31612/26164868.2(12).2020.06 (Ukrainian).

Mehlum MH, Liestøl K, Wyller TB et al. Blood pressure variability in hypertensive patients with atrial fibrillation in the VALUE trial. Blood Press. 2019; 28 (2): 77–83. doi.org/10.1080/ 08037051.2018.1524707.

Hijioka N, Kamioka M, Kazuaki A et al. Visit-to-visit Blood Pressure Variability Predicts Recurrence of Atrial Fibrillation in Patients With Hypertension. Circulation.2019; 140. A11808. https://www.ahajournals.org/doi/abs/10.1161/ circ.140.suppl_1.11808.

Hindricks G, Potpara T, Dagres N et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42 (5): 373–498. doi: 10.1093/eurheartj/ehaa612.

Boriani G, Savelieva I, Dan GA et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2015; 17: 11691196.

Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2018; 71: 2275–2279. https://doi.org/10.1161/ HYP.0000000000000065.

Soliman EZ, Safford MM, Muntner P et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014; 174: 107–114. doi: 10.1001/jamainternmed.2013.11912.

Soliman EZ, Lopez F, O’Neal WT et al. Atrial fibrillation and risk of ST-segmentelevation versus Non-ST-Segment-elevation myocardial infarction: The Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2015; 131: 1843–1850. https://doi.org/10.1161/ CIRCULATIONAHA.114.014145.

Kim TH, Yang PS, Kim D et al. CHA2DS2VASc score for identifying truly low-risk atrial fibrillation for stroke: a Korean nationwide cohort study. Stroke. 2017; 48: 2984–90. doi: 10.1161/ STROKEAHA.117.018551.

Lip G, Freedman B, De R et al. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017; 117: 1230–1239. doi: 10.1160/TH16-11-0876.

Stepina EV, Luk'janov MM, Bichurina MA et al. Prescription of medications influencing prognosis in atrial fibrillation with arterial hypertension, coronary heart disease, chronic heart failure, by the registry REKVAZA-CLINIC. Cardiovascular therapy and prevention. 2017; 16 (2): 33–38 http:// dx.doi.org/10.15829/1728-8800-2017-2-33-38.

Huxley RR, Lopez FL, Folsom AR et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123: 1501–1508. doi: 10.1161/CIRCULATIONAHA.110.009035.

Sharashova E, Wilsgaard T, Ball J et al. Long-term blood pressure trajectories and incident atrial fibrillation in women and men: the Tromsø Study. Eur. Heart J. 2020; 41(16):1554–1562. https://doi.org/10.1093/eurheartj/ehz234.

Lee SS, Kong KA, Kim D et al. Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. Eur. Heart J. 2017; 38: 2599–2607. doi: 10.1093/eurheartj/ehx316.

Wijesurendra RS, Casadei B. Seek and ye shall find subclinical atrial fibrillation in high-risk elderlypatients.Circulation.2017;136:1284–1287. doi: 10.1161/CIRCULATIONAHA.117.029397.

Ball J, Carrington MJ, McMurray JJ et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int. J. Cardiol. 2013; 167: 1807–1824. doi: 10.1016/j.ijcard.2012.12.093.

Nabauer M, Gerth A, Limbourg T et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009; 11: 423–434. doi: 10.1093/europace/eun369.

Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37: 2893–2962. doi: 10.1093/ eurheartj/ehw210.

Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat. Rev. Cardiol. 2017; 14: 627–628. doi: 10.1038/ nrcardio.2017.153.

Yalovenko MI, Khaniukov OO. Features of the arterial hypertension clinical course in patients with ischemic heart disease and atrial fibrillation. Мedical prospects. 2018; XXIII (4): 81–87. https:// doi.Org/10.26641/2307-404.2018.4.153005.

Thomas MC, Dublin S, Kaplan RC et al. Blood pressure control and risk of incident atrial fibrillation. American Journal of Hypertension.2008; 21 (10): 1111–1116. https:// doi.org/10.1038/ajh.2008.248.

Marott SCW, Nielsen SF, Benn M et al. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. European Heart Journal. 2014; 35 (18): 1205–1214. https://doi. org/10.1093/eurheartj/eht507.

Kim D, Yang PS, Kim T-H et al. Ideal Blood Pressure in Patients With Atrial Fibrillation. J. Am. Coll. Cardiol. 2018; 72 (11): 1233–1245. doi: 10.1016/j.jacc.2018.05.076.

Hiremath S, Vala DR, Roy T et al. Changing patterns in the prevalence and management of cardiovascular risk factors in India and their comparison with the rest of the world along with clinical outcomes at 5-year: An analysis of stable coronary artery disease patients from The Prospective Observational Longitudinal Registry of patients with stable coronary artery disease (CLARIFY) registry. Indian Heart Journal. 2018; 70 (3): 36–42. doi: 10.1016/j.ihj.2018.04.003.

Parcha V, Patel N, Kalra R et al. Incidence and Implications of Atrial Fibrillation Flutter in Hypertension. Hypertension. 2020; 75: 1483–490. 2020. https://doi.org/10.1161/ HYPERTENSIONAHA.120.14690.

Webb AJS, Rothwell PM Blood Pressure Variability and Risk of New-Onset Atrial Fibrillation A Systematic Review of Randomized Trials of Antihypertensive Drugs 2010. Stroke. 2010; 41: 2091–2093. https://doi.org/10.1161/ STROKEAHA.110.589531.

Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363: 2022–2031. doi: 10.1016/ S0140-6736(04)16451-9.

Emdin CA, Anderson SG, Salimi-Khorshidi G et al. Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults. International Journal of Epidemiology. 2017; 46 (1): 162–172. https://doi.org/10.1093/ije/dyw053.

Boev SS, Dotsenko NYa, Shekhunova IA et al. The role of blood pressure variability in hypertension in the development of cognitive impairment. Hypertension. 2019; 2 (64): 25–30. doi: 10.22141/2224-1485.2.64.2019.168751

Published
2021-12-20
How to Cite
Dotsenko, N. Y., Herasymenko, L. V., Shekhunova, I. A., Boev, S. S., MolodanА. V., Malinovskaya, A. Y., & Yatsenko, O. V. (2021). Variability of arterial hypertension as an additional factor to cardiovascular risk in atrial fibrillation. Modern Medical Technology, (4(51), 41-46. https://doi.org/10.34287/MMT.4(51).2021.8
Section
Original research

Most read articles by the same author(s)